The Annual Symposium of the CPRIT Therapeutic Antibody Core will take place noon – 5:30 p.m., Thursday, Dec. 1. The symposium will showcase successful research programs that have worked closely with the antibody core for identifying, validating, and developing cancer antibody drugs. The event provides an opportunity for learning the latest developments in the field from experts, growing connections among current collaborators with the core, and reaching out to potential new collaborators.

Talks will be presented in the Beth Robertson Auditorium of the Brown Foundation Institute of Molecular Medicine (IMM) Fayez S. Sarofim Research Building, 1825 Pressler St. Receptions will be held in the adjacent Willerson Discovery Hall.

A flier and preliminary agenda are available. Access the registration form directly here.

Agenda, flier, and registration also are available from the core website events page.

The CPRIT Therapeutic Antibody Core was established and is managed by Professors Zhiqiang An and Ningyan Zhang, who together have more than 30 years of experience in the drug discovery industry.

The core makes specialized antibody engineering technologies, services, and expertise available to Texas-based researchers. This support tackles major obstacles to advancing discoveries beyond the discovery stage toward the development of new treatments.

Key members of the core include a Scientific Advisory Board (SAB) and PI’s of associated projects.

Now in its second year of operation, the CPRIT Therapeutic Antibody core has enabled access to multiple antibody sources for drug lead identification, including phage displayed human antibody libraries. The core has additionally installed and begun operations with several specialized instruments.

Annually the core conducts an SAB meeting and a symposium. The CPRIT Therapeutic Antibody Core has become a member of the UT System iLabs Solutions Core Facility Management Software System, which streamlines financial management of the core.

Researchers who have benefited from the core include collaborator Chengcheng “Alec” Zhang, Departments of Physiology and Developmental Biology, UT Southwestern Medical Center. Zhang’s laboratory works to develop antibodies for the treatment of acute myeloid leukemia.

The long-term goal of the core is to continue providing statewide support and service to advance lead antibodies from academic laboratories to the stage of preclinical development. Toward this end, the core is currently seeking to establish new collaborations with researchers seeking to develop cancer therapeutic antibodies.

Any researcher interested in collaborating with the core may submit an application. Following initial consultation and prior to initiation, all projects will be reviewed for feasibility, appropriateness for the available core resources, cancer relevance and scientific merit. Approved requests for projects will be prioritized and scheduled accordingly.